Alpha-Adducin Gly460Trp Polymorphism and Clinical Efficacy of Indapamide in Uzbek Hypertensive Patients

ORIGINAL ARTICLE
Guzal J. Abdullaeva*, PhD; Gulnoz A. Khamidullaeva, PhD, ScD

The Republican Specialized Center of Cardiology, Tashkent, Uzbekistan

*Corresponding author: Guzal J. Abdullaeva, PhD.  The Republican Specialized Center of Cardiology; Tashkent, Uzbekistan. E-mail: guzal-abdullaeva@bk.ru

Published: September 12, 2015. DOI: 10.21103/Article5(3)_OA4

Abstract: 

The purpose of the present study was to evaluate pharmacogenetic aspects of the antihypertensive, cardioprotective and vasoprotective efficacy of Indapamide in association with the ADD1 Gly460Trp polymorphism in Uzbek hypertensive patients.

Materials and Methods: The study included 37 ethnic Uzbek patients (mean age of 47.14±9.54) with untreated hypertension (HT) of Grade 1 and 2 (ESH/ESC, 2013) and average HT duration of 5.7±4.33 years. All patients underwent clinical examination, echocardiography, Doppler sonography study, assessment of flow-mediated dilation (FMD) of the brachial artery and microalbuminuria (MAU) in daily urine. Genomic DNA was extracted from peripheral blood using the DiatomTM DNA Prep 200 Kit according to the manufacturer's protocol. The PCR-RFLP technique with visualization was performed to determine the ADD1 Gly460Trp polymorphism. Indapamide was prescribed as monotherapy for 12 weeks with an initial dose of 2.5 mg.

Results: A 12-week monotherapy with Indapamide in a daily dose of 2.5mg showed the high antihypertensive efficacy of this drug expressing a reliable decrease in absolute values of SBP and DBP independently as carrying of the ADD1 Gly460Trp polymorphism allele. Positive changes in LVM during therapy in patients of both allele groups were accompanied by an improvement in LV diastolic function with significant positive dynamics of IRP. The target normalization of FMD was achieved only in the presence of Gly-allele, as well as a significant decrease in IMT and MAU during treatment.

Conclusion: The results of our study showed high antihypertensive and cardioprotective efficacy of Indapamide treatment independently on carrying of the ADD1 Gly460Trp polymorphism. At the same time, we revealed certain advantages in the vasoprotective efficacy of Indapamide treatment in Uzbek hypertensive patients who are carriers of Gly-allele of the ADD1 Gly460Trp polymorphism.   

Keywords: 
hypertension; Indapamide; alpha-adducin Gly460Trp polymorphism.
References: 
  1. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al. Seventh report of the Joint National Committee on prevention, detection, evaluation and treatment of high blood pressure. J Hypertens 2003; 42(6):1206–52.
  2. Whitworth JA; World Health Organization, International Society of Hypertension Writing Group. 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens 2003;21(11):1983–92.
  3. Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Böhm M, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2013;34(28):2159-219.
  4. The diagnostics and treatment of arterial hypertension. Recommendations of Russian Medical Society of Arterial Hypertension and All-Russian Society of Cardiology. Kardiovas Terap Prof 2008; 7(6 Suppl 2). [in Russian].
  5. Mancia G, Laurent S, Agabiti–Rosei E, Ambrosioni E, Burnier M, Caulfield MJ, et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens 2009; 27(11):2121–58.
  6. Preobrajenskiy DV, Sidorencko BA. Treatment of arterial hypertension. Part I. Moscow; 1999 [Monograph in Russian].
  7. Sidorenko BA, Preobrajenskiy DV. Quick manual for the treatment of essential hypertension. Moscow; 1997 [Manual in Russian].
  8. Kaplan NM. Diuretics: cornerstone of antihypertensive therapy. Am J Cardiol 1996; 77(6):3B-5B.
  9. Sidorenko BA, Preobrajenskiy DV. Diagnostics and treatment of arterial hypertension. Part II. Mосква; 2000. [Monograph in Russian].
  10. Materson BJ, Reda DJ, Cushman WC, Massie BM, Freis ED, Kochar MS, et al. Single-drug therapy for hypertension in men. A comparison of six antihypertensive agents with placebo. The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. N Engl J Med 1993(13); 328:914–21.
  11. Luft FC, Weinberger MH. Heterogeneous responses to changes in dietary salt intake: the salt-sensitivity paradigm. Am J Clin Nutr 1997; 65(2 Suppl): 612S-617S.
  12. Matsuoka Y, Li X, Bennett V. Adducin: structure, function and regulation. Cell Mol Life Sci 2000; 57(6):884-95.
  13. Lin B, Nasir J, Mc Donald H, Graham R, Rommens JM, Goldberg YP, et al. Genomic organization of the human alpha-adducin gene and its alternately spliced isoforms. Genomics 1995; 25(1):93-9.
  14. Cusi D, Barlassina C, Azzani T, Casari G, Citterio L, Devoto M, et al. Polymorphisms of alpha-adducin and salt sensitivity in patients with essential hypertension. Lancet 1997; 349(9062):1353-57.
  15. Tamaki S, Iwai N, Tsujita Y, Nakamura Y, Kinoshita M. Polymorphism of alpha-adducin in Japanese patients with essential hypertension. Hypertens Res 1998; 21(1):29-32.
  16. Barlassina C, Norton GR, Samani NJ, Woodwiss AJ, Candy GC, Radevski I, et al. Alpha-adducin polymorphism in hypertensives of South African ancestry. Am J Hypertens 2000;13(6 Pt 1):719-23.
  17. Ju Z, Zhang H, Sun K, Song Y, Lu H, Hui R, Huang X. Alpha-adducin gene  polymorphism is associated with essential hypertension in Chinese: a case-control and family-based study. J Hypertens 2003; 21(10):1861-8.
  18. Kato N, Sugiyama T, Nabika T, Morita H, Kurihara H, Yazaki Y, et al. Lack of association between the alpha-adducin locus and essential hypertension in the Japanese population. Hypertension 1998; 31(3):730-3.
  19. Ishikawa K, Katsuya T, Sato N, Nakata Y, Takami S, Takiuchi S, et al. No association between alpha-adducin 460 polymorphism and essential hypertension in a Japanese population. Am J Hypertens 1998; 11(4 Pt 1):502-6.
  20. Alam S, Liyou N, Davis D, Tresillian M, Johnson AG. The 460Trp polymorphism of the human alpha-adducin gene is not associated with isolated systolic hypertension in elderly Australian Caucasians. J Hum Hypertens 2000; 14(3):199-203.
  21. Larson N, Hutchinson R, Boerwinkle E. Lack of association of 3 functional gene variants with hypertension in African Americans.  Hypertension 2000; 35(6):1297-300.
  22. He X, Zhu DL, Chu SL, Jin L, Xiong MM, Wang GL, et al. Alpha-adducin gene and essential hypertension in China. Clin Exp Hypertens 2001; 23(7):579-89.
  23. Castejon AM, Alfieri AB, Hoffmann IS, Rathinavelu A, Cubeddu LX. Alpha adducin polymorphism, salt sensitivity, nitric oxide excretion, and cardiovascular risk factors in normotensive Hispanics. Am J Hypertens 2003; 16(12):1018–24.
  24. Celermajer DS, Sorensen KE, Gooch VM, Spiegehalter DJ, Miller OI, Sullivan ID, et al. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet 1992; 340(8828):1111-5.
  25. Eliseyeva MR, Khamidullaeva GA, Srojidinova NZ, Abdullaeva GJ, Kurbanova DR, Karimova BSh, et al. Molecular genetics aspects of essential hypertension. Tashkent: SHARK; 2009. [Monograph in Russian].
  26. Barlassina C, Schork NJ, Manunta P, Citterio L, Sciarrone M, Lanella G, et al. Synergistic effect of alpha-adducin and ACE genes causes blood pressure changes with body sodium and volume expansion. Kidney Int 2000; 57(3):1083-90.
  27. Sciarrone MT, Stella P, Barlassina C, Manunta P, Lanzani C, Bianchi G, et al. ACE and α-adducin polymorphism as markers of individual response to diuretic therapy. Hypertension 2003;  41(3):398-403.
  28. Glorioso N, Manunta P, Filigheddu F, Troffa C, Stella P, Barlassina C, et al. The role of α-adducin polymorphism in blood pressure and sodium handling regulation may not be excluded by a negative association study.  Hypertension 1999; 34(4 Pt 1):649-54.
  29. Grant FD, Romero JR, Jeunemaitre X, Hunt SC, Hopkins PN, Hollenberg NH, et al. Low-renin hypertension, altered sodium homeostasis, and an alpha-adducin polymorphism.  Hypertension 2002; 39(2):191-6.
  30. Winnicki M, Somers VK, Accurso V, Hoffmann M, Pawlowski R, Frigo G, et al. Alpha-Adducin Gly460Trp polymorphism, left ventricular mass and plasma renin activity. J Hypertens 2002; 20(9):1771–7.
  31. Ciechanowicz A, Widecka K, Drozd R, Adler G, Cyrylowski L, Czekalski S. Lack of association between Gly460Trp polymorphism of alpha-adducin gene and salt sensitivity of blood pressure in Polish hypertensives. Kidney Blood Press Res 2001; 24(3):201–6.
  32. Turner ST, Chapman AB, Schwartz GL, Boerwinkle E. Effects of endothelial nitric oxide synthase, a-adducin, and other candidate gene polymorphisms on blood pressure response to hydrochlorothiazide. Am J Hypertens 2003; 16(10):834–9. 
  33. Manunta P, Lavery G, Lanzani C, Braund PS, Simonini M, Bodycote C et al. Physiological interaction between alpha-adducin and WNK1-NEDD4L pathways on sodium related blood pressure regulation. Hypertension 2008; 52(2):366-72.  

The fully formatted PDF version is available. 

Download Article

Int  J Biomed. 2015; 5(3):132-136. © 2015 International Medical Research and Development Corporation. All rights reserved.